We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
-10.7%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$11.7B
AUM Growth
-$3.17B
Cap. Flow
-$1.15B
Cap. Flow %
-9.88%
Top 10 Hldgs %
46.25%
Holding
136
New
17
Increased
36
Reduced
23
Closed
34

Sector Composition

Rank Sector Weight
1 Healthcare 51.69%
2 Communication Services 12.39%
3 Technology 10.92%
4 Industrials 5.44%
5 Financials 3.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
QTNT
76
DELISTED
Quotient Limited Ordinary Shares
QTNT
$9.88M 0.08%
62,500
VSTM icon
77
Verastem
VSTM
$610M
$9.82M 0.08%
+310,078
New +$7.78M
AKBA icon
78
Akebia Therapeutics
AKBA
$252M
$9.47M 0.08%
+1,250,000
New +$9.72M
PACB icon
79
Pacific Biosciences
PACB
$370M
$9.18M 0.08%
3,000,000
RC
80
Ready Capital
RC
$308M
$9.15M 0.08%
1,267,896
-349,274
-22% -$4.78M
CYTK icon
81
Cytokinetics
CYTK
$10.4B
$7.37M 0.06%
+625,000
New +$7.97M
DMTK
82
DELISTED
DermTech, Inc. Common Stock
DMTK
$6.81M 0.06%
605,255
-10,130
-2% -$124K
ADSW
83
DELISTED
Advanced Disposal Services Inc
ADSW
$5.79M 0.05%
+176,610
New +$5.79M
OPTN
84
DELISTED
OptiNose
OPTN
$3.5M 0.03%
52,032
-7,968
-13% -$803K
BEAM icon
85
Beam Therapeutics
BEAM
$2.84B
$3.06M 0.03%
+170,164
New +$3.7M
XRX icon
86
Xerox
XRX
$425M
$2.46M 0.02%
130,000
AGTC
87
DELISTED
Applied Genetic Technologies Corporation
AGTC
$1.92M 0.02%
+586,497
New +$3.09M
BRMK.WS
88
DELISTED
Broadmark Realty Capital Inc. Warrants, each exercisable for one fourth (1/4th) share of Common Stock at an exercise price of $2.875 per quarter share
BRMK.WS
$1.58M 0.01%
7,174,613
GOSS icon
89
Gossamer Bio
GOSS
$87M
$1.01M 0.01%
100,000
-400,000
-80% -$5.22M
RVMD icon
90
Revolution Medicines
RVMD
$44B
$454K ﹤0.01%
+20,733
New +$574K
GOL
91
DELISTED
Gol Linhas Aéreas Inteligentes S.A. American Depositary Shares (Each representing Ten Preferred Shares)
GOL
$367K ﹤0.01%
+85,838
New +$1.09M
EIGR
92
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$341K ﹤0.01%
1,670
-34,815
-95% -$11.1M
PHAS
93
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$280K ﹤0.01%
84,502
-915,498
-92% -$4.19M
ABEO icon
94
Abeona Therapeutics
ABEO
$413M
-80,000
Closed -$6.54M
AMRN
95
CALL
Amarin Corp
AMRN
$303M
-50,000
Closed -$21.4M
AXSM icon
96
Axsome Therapeutics
AXSM
$10.9B
-442,222
Closed -$45.7M
CVS icon
97
CVS Health
CVS
$122B
-750,000
Closed -$55.7M
CYCN icon
98
Cyclerion Therapeutics
CYCN
$16.7M
-17,500
Closed -$952K
GEN icon
99
Gen Digital
GEN
$17.5B
-720,000
Closed -$18.4M
HRTX icon
100
Heron Therapeutics
HRTX
$92.9M
-875,000
Closed -$20.6M

Similar funds

Farallon Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Farallon Capital Management held 136 positions worth $11.7B, down 21% from $14.8B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Farallon Capital Management withdrew a net $1.15B in Q1 2020, closing 34 positions and reducing 23 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $793M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 38% a quarter earlier, followed by Communication Services and Technology.

Against the trend, Farallon Capital Management opened a new position in Centene worth $431M.

  • Farallon Capital Management's largest Q1 2020 buy was Centene: 7,250,000 shares worth $431M.
  • Farallon Capital Management added most to IQVIA in Q1 2020, an estimated $269M increase.
  • Farallon Capital Management's biggest Q1 2020 reduction was MyoKardia, Inc. Common Stock, cutting an estimated $104M.
  • Farallon Capital Management fully exited Wellcare Health Plans, Inc. in Q1 2020, selling an estimated $793M.
  • Farallon Capital Management's ten largest holdings make up 46% of its $11.7B portfolio in Q1 2020.
  • Farallon Capital Management opened 17 new positions and closed 34 in Q1 2020.
  • Farallon Capital Management's portfolio value fell 21% quarter-over-quarter to $11.7B.

Based on Farallon Capital Management's 13F filing for Q1 2020, filed 15 May 2020.